Calendar

17 Mar. 2025, 13:00-16:00

PhD defence: Lisa Charlotte Smith

Evaluating the use of Immersive Virtual Reality in the Treatment of Auditory Verbal Hallucinations- Reporting on the results of the Challenge trial and providing an overview of the field

17 Mar. 2025, 14:00-17:00

PhD defence: Marie Hvelplund Kristiansen

The JAK2V617F Mutation as a Novel Risk Factor for Ischemic Stroke (JAK2Stroke) - Studies on the association between the JAK2V617F allele burden, thromboinflammation and additional somatic mutations in ischemic cerebrovascular patients

17 Mar. 2025, 15:00-18:00

PhD defence: Nora Borislavova Vladimirova

Musculoskeletal involvement in patients with inflammatory bowel disease - symptoms, clinical and imaging findings

18 Mar. 2025, 9:00-12:00

PhD defence: Qing Gao

Singlet Oxygen Mediated Disulfides and Protein Oxidation

19 Mar. 2025, 12:30-15:30

PhD defence: Anton Berg Hansen

Development of a microfluidic system for sub-zero temperature hydrogen/deuterium exchange mass spectrometry - possibilities, challenges and limitations

20 Mar. 2025, 10:00

PhD defence: Haika Monica Osaki

Navigating Challenges in Urban Maternity Care: Collective Coping and the Co-creation of Clinical Guidelines in Tanzania

21 Mar. 2025, 10:00-13:00

PhD defence: Anna Campana

The Dopamine Transporter in the Context of Neuropsychiatric Disorders - Structure-function disturbance, psychostimulants response and Zn2+-mediated modulation

21 Mar. 2025, 13:00-16:00

PhD defence: Tanya Ramdal Techlo

Genomic approaches for finding genetic causes in migraine and epilepsy

21 Mar. 2025, 14:00-17:00

PhD defence: Lærke Cecilie Ragborg Nielsen

The use of supplemental interbody fusion in Adult Spinal Deformity patients

21 Mar. 2025, 14:00

Anne-Vibeke Lænkholm´s Doctoral Defence

On Friday 21 March 2025 at 14:00 MD Anne-Vibeke Lænkholm will defend her doctoral dissertation to be awarded the doctoral degree in medical science (dr.med.) (DMSc.).

Dissertation

Estrogen receptor (ER) and associated prognostic factors in ER positive HER2 normal postmenopausal early breast cancer patients –The Danish Breast Cancer Group experience with focus on anti-hormonal treatment